Peptide Sequences for HCC Immunotherapy via T-Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatocellular carcinoma (HCC) lack effective immunotherapeutic options, with limited therapeutic vaccines and high resistance to chemotherapeutics, resulting in poor prognosis and limited survival benefits.
Innovation Solution
Development of a pharmaceutical composition comprising specific peptide sequences derived from HLA class I and class II molecules of human tumor cells, which can be used to stimulate anti-tumor immune responses, either alone or in combination with other peptides, as part of vaccine compositions or for immunotoxin therapy, and include activated cytotoxic T lymphocytes and antibodies targeting the MHC/peptide complex.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat HCC, then tumor cells can be attacked, but high resistance to chemotherapeutics develops resulting in poor treatment efficacy
Solution Approach 1:
The patent uses peptide-MHC complexes as intermediaries to activate cytotoxic T-lymphocytes, which then recognize and destroy tumor cells. This immunological approach bypasses the chemotherapeutic resistance mechanism by engaging the patient's own immune system rather than directly attacking tumor cells with drugs to which they have developed resistance.
Solution Approach 2:
The invention harnesses the patient's own immune system to fight the cancer. By using autologous dendritic cells loaded with tumor-derived peptides, the therapy enables the patient's immune cells to self-organize and attack tumor cells, eliminating the need for external chemotherapeutic agents that face resistance.
2Reliability
If limited immunotherapy trials are conducted with existing vaccines, then some immune activation occurs, but only limited improvements in clinical outcomes are achieved
Solution Approach 1:
The patent employs multiple distinct peptide sequences derived from different tumor-associated antigens (MAGE-A4, BAGE, GAGE family members) to target different epitopes on tumor cells. This multi-epitope approach ensures that if the immune system responds to one peptide, other peptides provide backup targets, overcoming the limited efficacy of single-antigen vaccines.
Solution Approach 2:
The invention combines multiple peptide sequences from different cancer-testis antigen families into a composite vaccine formulation. This composite approach integrates antigens from MAGE, BAGE, and GAGE families to create a multi-component immunotherapy that addresses the limitations of monovalent vaccines through synergistic immune activation.
3Reliability
If the peptide composition is designed to target specific HLA class I and class II molecules, then targeted immune responses against HCC cells are induced, but the complexity of identifying suitable peptide sequences increases
Solution Approach 1:
The patent selects peptide sequences that bind to common HLA alleles (HLA-A*02:01, HLA-A*24:02, HLA-B*07:02) that are present in a significant portion of the population. By targeting these frequently occurring HLA types, the vaccine design achieves broad applicability while maintaining focused immune responses against HCC cells, balancing specificity with population-wide relevance.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The current invention relates to a pharmaceutical composition comprising a peptide of the sequence according to SEQ ID No. 303 together with at least one suitable carrier and/or excipient for use in the treatment of Hepatocellular carcinoma cancer (HCC).